8-K: Sangamo Therapeutics Files for Chapter 11 Bankruptcy

Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection and its Nasdaq delisting request has been denied, leading to trading on the OTCQB.

Summary

• Sangamo Therapeutics, Inc. has filed for Chapter 11 bankruptcy protection on June 23, 2026.
• The company's common stock was suspended from trading on Nasdaq on May 5, 2026, and now trades on the OTCQB Venture Market under the symbol SGMOQ.
• Nasdaq has denied the company's request to continue its listing on The Nasdaq Capital Market.
• The company is operating as a debtor-in-possession and is seeking to sell all or substantially all of its assets through an auction process.
• Key dates for the asset sale process include a Bid Deadline of August 4, 2026, an Auction on August 10, 2026, and a Sale Hearing on August 20, 2026.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this filing as extremely negative, reflecting a critical financial situation leading to bankruptcy and delisting.

Negatives

• The company's common stock has been delisted from Nasdaq and is now trading on the OTCQB Venture Market.
• Nasdaq has denied the company's request to continue its listing on The Nasdaq Capital Market.
• The company has filed for Chapter 11 bankruptcy protection, indicating significant financial distress.

Risks

• The company faces the risk of not finding a successful bidder for its assets, potentially leading to liquidation.
• The bankruptcy proceedings and asset sale process introduce significant uncertainty for stakeholders.
• Continued trading on the OTCQB Venture Market may result in lower liquidity and investor interest compared to Nasdaq.

Future Outlook

The company's objective in the Chapter 11 case is to maximize value for its stakeholders, which may be achieved through the sale of all or substantially all assets to the highest bidder or bidders, and/or through a reorganization with a chapter 11 plan sponsor.

Industry Context

StockSavvy.ai notes that this filing reflects a severe financial distress scenario for Sangamo Therapeutics, a company operating in the highly competitive and capital-intensive biotechnology sector. The Chapter 11 filing and Nasdaq delisting indicate significant challenges in funding operations and meeting listing requirements, a situation not uncommon for early-stage or development-focused biotech firms facing clinical or commercial hurdles.

Legal Proceedings

• Voluntary petition for relief under Chapter 11 of the Bankruptcy Code filed on June 23, 2026 (Case No. 26-10989).

Stakeholder Impact

• Shareholders face significant dilution and potential loss of investment due to bankruptcy and asset sale.
• Creditors will be subject to the bankruptcy process for recovery of debts.
• Employees may face uncertainty regarding job security and future employment.
• Suppliers may experience disruptions in payment and future business relationships.

Next Steps

• The company will proceed with the asset sale process under court supervision.
• Potential bidders must submit bids by August 4, 2026.
• An auction will be held on August 10, 2026, if multiple qualified bids are received.
• A Sale Hearing is scheduled for August 20, 2026, to approve the successful bids.

Key Dates

Recommendation

Given the Chapter 11 bankruptcy filing, the denial of Nasdaq listing, and the subsequent trading on the OTCQB, the company is in severe financial distress. The asset sale process introduces significant uncertainty, and the outlook for existing shareholders is extremely bleak, warranting a sell recommendation.

Keywords

Chapter 11 Bankruptcy, Sangamo Therapeutics, Asset Sale, Nasdaq Delisting, OTCQB, Securities and Exchange Commission, Form 8-K, Biotechnology